

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Exploring mechanochemical parameters using a DoE approach: Crystal structure solution from synchrotron XRPD and characterization of a new praziquantel polymorph

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1730025> since 2020-02-22T23:44:23Z

Published version:

DOI:10.1016/j.ejps.2019.105084

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1
2
3
4 **A new praziquantel polymorph discovered by means of a DoE approach:**
5
6 **crystal structure solution from Synchrotron XRPD and characterization**
7
8
9

10 *Debora Zanolla,¹ Beatrice Perissutti,^{1*} Paolo Cerreia Vioglio,² Michele R. Chierotti,³ Lara Gigli,⁴ Nicola*
11 *Demitri,⁴ Nadia Passerini,⁵ Beatrice Albertini,⁵ Erica Franceschini,⁶ Jennifer Keiser,⁷ Dario Voinovich¹*
12
13
14

15
16
17 ¹*University of Trieste, Dept. of Chemical and Pharmaceutical Sciences, P.le Europa 1, Trieste, Italy*

18 ²*Aix-Marseille Université, CNRS, ICR (UMR 7273), 13397 Marseille cedex 20, France*

19 ³*University of Torino, Dept. of Chemistry and NIS Centre, V. Giuria 7, Torino, Italy*

20 ⁴*Elettra-Sincrotrone Trieste, S.S. 14 Km 163.5 in Area Science Park, Basovizza–Trieste, Italy*

21 ⁵*University of Bologna Dept. of Pharmacy and BioTechnology, Via S. Donato 19/2, Bologna, Italy*

22 ⁶*University of Padova Dept. of Pharmaceutical and Pharmacological Sciences, via Marzolo 5, Padova, Italy*

23 ⁷*Swiss Tropical and Public Health Institute Helminth Drug Development Unit, Dept. Medical Parasitology*
24 *and Infection Biology, Basel, Switzerland*

25 ⁸*Universität Basel, Petersplatz 1, P.O. Box, CH-4001 Basel, Switzerland*
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41
42 ** Corresponding author:*

43
44 *Beatrice Perissutti: E-mail address: bperissutti@units.it;*

45
46
47 *Tel. +39 040 558 3106; ORCID 0000-0002-5766-4014*
48
49
50
51
52
53
54
55
56
57
58
59

60
61
62 **ABSTRACT**
63

64
65 To explore the experimental design space (in terms of frequency and time of milling) nearby the
66 milling parameters of Praziquantel (PZQ) polymorph B formation, a rotated Doehlert matrix was
67 employed. Three experimental responses were evaluated on ground samples: two quantitative ones,
68 the median particle size by Laser Light scattering (LLS) and the drug recovery by HPLC, and a
69 qualitative dependent variable, the obtained PZQ crystal form, characterized through X-Ray Powder
70 Diffraction (XRPD) and confirmed by Differential Scanning Calorimetry (DSC) and
71 Thermogravimetric analysis (TGA). The temperature inside the jars during the milling process was
72 continuously monitored by using jars equipped with temperature sensors, allowing to consider the
73 solid state obtained in each experimental point in the light of the specific temperature of the
74 process. This explorative analysis led to the discovery of a novel PZQ polymorph, named Form C,
75 which was produced without degradation and then fully characterized also by means of Synchrotron
76 XRPD, Polarimetric, FT-IR, SS-NMR, ESEM, saturation solubility and *in vitro* dissolution rate
77 analyses. Crystal structure was solved from XRPD data and its geometry was optimized by DFT
78 calculations (CASTEP). Finally, Form C activity against adult schistosoma mansoni in comparison
79 to raw PZQ was tested in vitro, and its physical stability was checked. The new polymorph,
80 crystallizing in space group I2/c, physically stable for 2 months, showed a m.p. of 106.84°C and
81 displayed excellent biopharmaceutical properties (water solubility of 382.69±9.26 mg/l and fast
82 dissolution: t90% of about 50 min), while preserving an excellent activity against adult schistosoma
83 mansoni.
84
85
86
87
88
89
90
91
92
93
94

95 **KEYWORDS:**

96 Praziquantel; crystalline polymorph; mechanochemistry; Doehlert design; median particle size; drug
97 recovery; solubility; bioactivity; crystal structure solution; GIPAW; thermo jars.
98
99

119
120
121
122
123 **INTRODUCTION**
124
125
126

127 Praziquantel (PZQ) (which structure is reported in Figure 1) is the only drug marketed for treatment and in
128 so-called preventive chemotherapy against *Schistosoma* spp. infections [1]. According to the
129 Biopharmaceutics Classification System, PZQ belongs to the class II drugs, because of its high permeability
130 and low solubility (0.4 mg/mL) [2, 3]. PZQ has also a high first pass metabolism (1-3 h), which converts the
131 active R-PZQ into inactive metabolites very rapidly [4,5]. Therefore a high dosage (40 mg/Kg) is required to
132 be effective by using big tablets [6]. This fact, combined with the disgusting taste of the drug, results in a
133 limited compliance to the therapy, especially in children, representing more than 50% of patients. To
134 overcome these problems, a crystalline polymorph of PZQ, which is based on the commercial racemic PZQ
135 and obtained by neat grinding in a vibrational mill in suitable process conditions, was recently prepared [7].
136 Its structure was solved from the synchrotron XRPD pattern resulting in a centrosymmetric $C2/c$ unit cell
137 with one crystallographically independent molecule. Form B, indexed as TELCEU01 (CCDC 1557658) [7]
138 in the Cambridge Structural Database [8], has double solubility and intrinsic dissolution rate (IDR) in
139 comparison with raw PZQ [7], and similar in vivo efficacy to the standard PZQ [9].
140
141
142
143
144
145
146




Figure 1. Chemical structure of Praziquantel (PZQ) with atom numbering.

In this paper, the nearby milling conditions of Form B production will be deeply investigated by using a design of experiments (DoE), and in particular a Doehlert design. This design, proposed by Doehlert in 1970 [10], is an experimental design for second order models providing a uniform shell design. The Doehlert matrix, derived from the simplex optimization, has been frequently used in the optimization processes of many fields because of the uniformity of the points in the experimental domain that permits to identify a response surface by means of a minimum of experiments [11,12]. The comparison among other second-order designs (such as Central Composite Design or Box–Behnken) has showed that the Doehlert design is the most efficient of the three [13]. The Doehlert matrix has been widely used for optimization of analytical or

178
179
180 extraction methods [14,15]; in materials science many of the papers reporting the use of a Doehlert matrix
181 involve optimization or explorative analysis of process and/or formulation variables, and quality control in
182 the development of pharmaceutical product [16-18]. Not yet documented is the use of such designs in the
183 search of new polymorphic forms, and generally very poorly documented nowadays is the use of DoE
184 approach in crystal engineering [19] and mechanochemistry [20,21]. In this case the Doehlert design will be
185 applied to explore the experimental design space of Form B formation by neat grinding, defined by 2 process
186 variables: time and frequency of milling. In fact, while the rules which decide the nature of transformations
187 induced by milling are not yet clearly established, it seems that the main physical parameters involved are
188 milling intensity and milling temperature (both related to frequency and duration of the milling) [22].

193
194 The Doehlert design can be proposed in the classical hexagonal form or in its rotated form, where each point
195 is characterized by different values of the selected variables [11], the latter being the experimental design
196 chosen for this work. PZQ crystal form at the end of the process was considered as qualitative experimental
197 response of the explorative analysis. The median particle size and the drug recovery of the ground samples
198 were also studied as a function of the variation of time and frequency of milling. Then the solid state
199 obtained in each experimental point was considered in the light of the temperature measured in special
200 thermojar in different milling conditions.

204
205 This explorative analysis led to the discovery of an additional PZQ anhydrous polymorph, namely Form C,
206 which was obtained in quantitative yield. The new form C was fully characterized by means of Differential
207 Scanning Calorimetry (DSC), Thermogravimetric analysis (TGA), Synchrotron X-Ray Powder Diffraction,
208 (XRPD) Polarimetric and High performance liquid chromatography analyses (HPLC), solid-state NMR
209 (SSNMR) and FT-IR studies. Particle morphology was studied by ESEM. Crystal structure was solved from
210 XRPD data and its geometry was optimized by GIPAW-DFT calculations. Water saturation solubility and in
211 vitro dissolution studies were carried to test biopharmaceutical properties. Finally, its activity against adult
212 *Schistosoma mansoni* in comparison to PZQ was tested in vitro, and its physical stability checked over a
213 period of 4 months.

218 219 **2. Materials and Methods**

220 221 **2.1 Materials**

222
223 Praziquantel (PZQ) Ph. Eur. grade ((11bRS)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4-H-
224 pyrazino[2,1-a]isoquinolin-4-one) was a kind gift from Fatro S.p.A. (Bologna, Italy). PZQ impurity A (2-
225 Benzoyl-1,2,3,6,7,11b-hexahydro-4-H-pyrazino[2,1-a]isoquinolin-4-one) and impurity B (2-
226 Cyclohexanecarbonyl-2,3,6,7-tetrahydro-pyrazino[2,1-a]isoquinolin-4-one) were Ph. Eur. grade and obtained
227 from Endotherm GmbH (Saarbruecken, Germany). HiPersolv Chromanorm Methanol (Ph. Eur. for HPLC
228 Gradient Grade) and Ethanol (Ph. Eur.) were acquired from Sigma Aldrich.

232 233 **2.2. Explorative analysis using Doehlert experimental Design**

237
238
239 Starting Praziquantel (PZQ form A, indexed as TELCEU in the Cambridge Structural Database (CCDC
240 896767) [23] was milled on its own, by neat grinding, in a vibrational mill-Retsch MM400 (Retsch GmbH)
241 which was equipped by 2 screw-type zirconium oxide 35 ml jars. Based on earlier studies [7, 24], a powder
242 amount of 0.8 g was introduced in each milling jar, three spheres of 15 mm (weighing 10.72 g each) were
243 used as milling media and a ceramic material like zirconium oxide was selected for the jars and spheres,
244 allowing for a high energy input.
245
246
247

248
249 Time (x_1) and frequency (x_2) of milling were varied according to an experimental design. In particular, the
250 experimental design space around Form B formation (TELCEU01)[7] was explored by means of a rotated
251 Doehlert matrix, designed using NEMRODW software [25]. The conditions of polymorph B formation (240
252 min at 20 Hz) were chosen as the central point of the Doehlert matrix. The experimental domain and the
253 experimental plan are shown in Table 1. For two variables, the Doehlert design consists of one central point
254 and six points forming a regular hexagon, and therefore situated on a circle; three additional points were
255 considered inside the design space, to reach a total number of 10 experiments. The experiments were carried
256 out in random order (also reported in same table) and each milling trial was simultaneously carried out in
257 both jars. The room temperature was thermostated at 22°C. As first experimental response of the explorative
258 analysis (y_1) a qualitative dependent variable was chosen: the obtained PZQ crystal form (as it resulted from
259 XRPD analysis, and confirmed by DSC and TGA analyses, according to paragraph 2.2.1.). In addition two
260 quantitative variables were selected: the median particle size of the ground samples (y_2) (as determined by
261 Laser Light Scattering analysis, according to paragraph 2.2.2.) and drug recovery after milling (y_3) (as
262 determined by HPLC analysis, according to paragraph 2.2.3.).
263
264
265
266
267
268
269

270 After the treatment, the solid products were stored in the dark at 25°C in desiccators over anhydrous calcium
271 chloride for further characterisation and processings.
272

273 274 **2.2.1. Evaluation of (y_1): Solid state analyses**

275 276 *X-Ray powder diffraction (XRPD)*

277
278 All ground samples were analyzed by X-ray powder diffraction using a Panalytical X'Pert Pro
279 Diffractometer with Ni-filtered Cu K α radiation ($\lambda=1.5418 \text{ \AA}$), the detector was a RTMS X'celerator. The
280 preparation of the samples consisted in pressing about 20-30 mg of powder over a glass slide to have a flat
281 surface. The data were collected in a 2θ range of 3-40 degree.
282
283

284 285 *Differential Scanning Calorimetry (DSC)*

286
287 Each sample was analyzed using a Mettler DSC TA 4000 (Greifensee, Switzerland) connected to a
288 calorimetric cell Mettler DSC20 and using STARe software version 9.30 for data analysis. Prior to analysis
289 the instrument was calibrated with Indium, Zinc and Lead for the temperature and with Indium for the
290
291
292
293
294
295

296
297
298 enthalpy quantification. In each analysis, about 2 mg of the sample was accurately weighted, placed in a 40
299 μL aluminum pan with perforated lid and heated $10^\circ\text{C}/\text{min}$ from 30 to 160°C under air atmosphere.
300

301 *Thermogravimetric Analysis (TGA)*

302
303
304 The thermogravimetric analysis was conducted using a Mettler Toledo TGA/SDTA851e: about 10-15 mg of
305 the sample accurately weighted were placed in aluminum crucible ($100 \mu\text{L}$); then the heating was performed
306 from 25 to 220°C , with a heating rate of $10^\circ\text{C}/\text{min}$ under nitrogen atmosphere. To calculate the weight loss
307 from the weight-temperature diagram, STARe software 11.00 was used.
308
309

310 *Sample temperature continuous measurement during grinding*

311
312
313 The temperature inside the jar during the milling process was continuously monitored by using the
314 ThermoJar set specific system (InSolido Technologies j.d.o.o., Zagreb, Croatia). It is composed by a PMMA
315 jar equipped with a RTD (Pt-100) thermal sensor, a wireless infrared emitter with a dedicated logging system
316 and software to collect, analyze and graphic the data (LogOS). The system is completed by another PMMA
317 jar which is used to balance the milling system. In this way, the temperature measurements are specifically
318 referred to the inert part of the jar, giving a description of its progress during time. The measurements were
319 performed every second for 300 min grinding at 15-18-20-22-25 Hz, corresponding to the milling
320 frequencies of the explorative analysis.
321
322
323
324

325 The powder temperature at the end of the process (300 min) both in the PMMA jars and in the conventional
326 zirconium oxide jars was also measured using a 35XP-A Amprobe K-type thermocouple (Amprobe, Test
327 Tools Europe, Glottertal, Germany).
328
329

330 **2.2.2. Evaluation of (y_2): Laser Light Scattering Analysis**

331
332
333 The median particle size was measured by laser diffraction technique (Malvern Mastersizer Hydro 2000,
334 Malvern Instruments, UK). The samples were dispersed in a small amount of distilled water containing 0.5%
335 (w/w) of polysorbate 80 (Sigma Aldrich, Milan, Italy) and sonicated for one min. Sample dispersion was
336 then poured in Mastersizer Hydro 2000 dispersion unit containing about 200 ml of water until the
337 obscuration reaches a value between 10% and 20%. The analysis were performed in triplicate using a
338 dispersion unit controller set to 1800 rpm. Particle size distributions were then calculated using a particle
339 refractive index value of 1.700.
340
341
342

343 **2.2.3. Evaluation of (y_3): Determination of drug recovery after milling**

344
345
346 The content of PZQ was assayed in each ground sample by means of a reverse-phase HPLC-UV by adapting
347 a method already reported in literature [26] and slightly modified as previously reported [7]; the system had
348 two delivery pumps (LC-10 ADVP, Shimadzu, Japan), an autosampler (SIL-20A, Shimadzu, Japan) a UV-
349 vis detector (SPD-10Avp, Shimadzu, Japan); the data were acquired at a fixed wavelength of 220 nm using
350
351
352
353
354

355
356
357 an interface (SCL-10Avp, Shimadzu, Japan) and analyzed with Ez-Star software; the column used was a
358 Kinetex 5 μm C18 (150 x 4.60 mm, Phenomenex, Bologna). The mobile phase used was a mixture of
359 methanol:water (65:35 v/v), purged at 1 ml/min. Injected volume was 20 μl . PZQ retention time was 5.5 min
360 while the total run time for each sample was set at 12 min. Prior to analysis, a linear calibration curve with
361 $r^2=0.99996$ was obtained for PZQ under these conditions using different concentrations of the drug from 0.3
362 to 10 mg/mL. Each day, a standard solution (with a concentration of 2.5 mg/L) was prepared by dissolving
363 about 10 mg of PZQ accurately weighted in Methanol of HPLC grade (20 mL) and diluting the solution
364 1:200 with the mobile phase. Moreover, two additional calibration curves were obtained respectively for the
365 relative impurity indicated in the Eur. Ph. (Ed. 8.0), impurity A ($r^2=0.9993$) and impurity B ($r^2=0.9994$),
366 which were identified at the retention time of 3.45 min and 11.2 min. The reference solution did not report
367 any of these impurities. Results were averages of four replicates.
368
369
370
371
372
373

374 **2.4. Preparation of New Form C**

375
376 Form C was obtained by neat grinding using the process conditions of experimental points EXP 3, 6, 8 and
377 10 of the experimental design. Nevertheless, the conditions of EXP 10 were taken as the standard ones, due
378 to a slightly higher crystallinity.
379
380

381 **2.4.1. Evaluation of Form C**

382 *Polarimetric analyses*

383
384
385
386 Optical rotations of the samples were measured on a Polarimeter Jasco P-2000 (Lecco, Italy), with a $\lambda = 589$
387 nm and a concentration of 1 g/100 ml in ethanol, according to the method reported in literature [27, 28]
388 slightly modified by using ethanol in place of CHCl_3 , as previously described [7].
389
390

391 *Synchrotron X-Ray powder diffraction*

392
393 Form C was analyzed using synchrotron XRPD at Elettra X-ray diffraction beamline (XRD1) [29] in order to
394 obtain data suitable for the crystal structure solution and refinement. Diffraction patterns with improved
395 resolution and signal to noise ratio have been obtained, compared to the conventional laboratory source
396 results. Data were collected in transmission mode packing the powder in borosilicate capillaries with a
397 diameter of 300 μm . Patterns were collected at room temperature using a monochromatic wavelength of
398 0.700Å (17.71 KeV), 200*2000 μm^2 spot size on a hybrid-pixel Dectris Pilatus 2M area detector (Dectris
399 Ltd., Baden-Daettwil, Switzerland). The patterns were then integrated using Fit2D program [30-31], after
400 calibrating the hardware setup with LaB_6 standard reference powder (NIST 660a).
401
402
403
404

405 *Solid-state NMR measurements*

406
407
408 Solid-state NMR measurements of Form C were performed on a Bruker Avance II 400 instrument operating
409 at 100.65 and 40.55 MHz for ^{13}C and ^{15}N nuclei, respectively. Cylindrical 4 mm o.d. zirconia rotors with a
410
411
412
413

414
415
416 sample volume of 80 μL were employed and spun at 12 (^{13}C) and 9 (^{15}N) kHz. All experiments employed the
417 RAMP-CP pulse sequence (^1H 90° pulse=3.05 μs) with the TPPM ^1H decoupling with a rf field of 75 kHz
418 during the acquisition period. 124 (^{13}C) or 5700 (^{15}N) transients were acquired with 3 (^{13}C) or 4 (^{15}N) ms of
419 contact time and a relaxation delays of 20 s. ^{13}C and ^{15}N chemical shifts were referenced with the resonance
420 of hexamethylbenzene (^{13}C methyl signal at 17.4 ppm) and NH_4SO_4 (^{15}N signal at -355.8 ppm with respect to
421 CH_3NO_2).

425 *GIPAW-DFT calculations*

426
427
428 Periodic lattice calculations were performed using CASTEP [32] (Academic Release version 17.2) which
429 exploits a plane-wave and pseudopotential approach within density functional theory (DFT).[33] The
430 absolute chemical shieldings were calculated using the GIPAW algorithm [34] as implemented in the
431 CASTEP code.

432
433
434 The geometry optimization and the NMR chemical shielding calculations were carried out employing the
435 generalized gradient approximation (GGA) PBE exchange-correlation functional [35] with the semi-
436 empirical dispersion scheme [36] TS [37] and ultrasoft pseudopotentials which were generated on the fly.
437 The plane-wave cut-off energy was set equal to 700 eV, and the Brillouin zone was automatically sampled
438 using a Monkhorst-Pack grid with a k-point spacing of 0.05 \AA^{-1} .

439
440 The geometry optimization was performed starting from the structure of the Form C polymorph determined
441 from synchrotron XRPD (space group I2/c, 376 atoms in the unit cell, $Z' = 1$), transformed in the equivalent
442 space group C2/c (applying the transformation matrix [-1 0 -1, 0 -1 0, 0 0 1] to the 376 atoms in the unit cell,
443 $Z' = 1$) for an easiest calculation set up. The experimental unit cell parameters were kept fixed during the
444 optimization, as they were considered to be of acceptable quality. The convergence tolerances for the total
445 energies, forces and displacements were set to $4.00 \cdot 10^{-64} \text{ eV atom}^{-1}$, $0.015 \text{ eV \AA}^{-1}$, and $5 \cdot 10^{-4} \text{ \AA}$ 0.001 \AA ,
446 respectively. The refined structure was used in the subsequent chemical shielding calculation.

447
448 The absolute ^{13}C and ^{15}N isotropic chemical shieldings (σ_{iso}) were calculated using the same functional and
449 parameters as those used for the geometry optimization. The plane-wave cut-off energy was set to 800 eV.
450 The σ_{iso} were converted into the corresponding isotropic chemical shifts, $\delta_{\text{iso}}(\text{calc})$, using the following
451 conversion: $\delta_{\text{iso}}(\text{calc}) = \sigma_{\text{ref}} - \sigma_{\text{iso}}$. Here, σ_{ref} is the reference shielding, obtained by plotting the
452 experimental chemical shifts $\delta_{\text{iso}}(\text{exp})$ against the GIPAW-calculated chemical shieldings. A linear
453 regression model with slope constrained to (-1) was applied to find the best fit to the data (see Figures S1
454 and S2 in the Supporting Information). The value of σ_{ref} is determined by the intercept with the y axis [38-
455 39]. The obtained values of σ_{ref} are 1712.2 ppm and 190.5 ppm for ^{13}C and ^{15}N , respectively.

466 *FTIR Spectroscopy*

473
474
475 FTIR spectrum of Form C was acquired at the solid state using a Perkin Elmer System 2000 FT-IR (Perkin-
476 Elmer, Monza, Italy). The sample was mixed with anhydrous KBr (Anhydrous potassium bromide
477 UVASOL, Sigma-Aldrich, Milan, Italy) in an agate mortar and then pressed with an hydraulic press for 2
478 min at 10 Ton to obtain homogeneous and transparent discs. The analysis was conducted from 400 to 4000
479 cm^{-1} with a resolution of 2 cm^{-1} and total scan number of 10.
480
481
482

483 *Morphological analysis*

484

485 The morphology of Form C was studied by an ESEM (Quanta 200 FEI) which permits the imaging of the
486 substance with no prior specimen preparation. The analysis were performed under low-vacuum conditions in
487 secondary electrons with a working distance of approximately 13 mm and an accelerating voltage of 20 kV.
488 For comparison purposes, a JEOL JSM-5510LV (JEOL LTD, Welwyn Garden City, UK) Scanning Electron
489 Microscope was used for imaging raw PZQ and Form B.
490
491
492

493 *Determination of Drug Solubility*

494

495 To determine the water solubility of Form C, saturated solutions were prepared in distilled water and kept
496 under agitation in the dark for 48 hours at 20°C . Subsequently, the solutions were filtered with a membrane
497 of $0.2 \mu\text{m}$ pore size, diluted 1:200 with the mobile phase (65% MeOH - 35% H_2O), injected in the HPLC
498 instrument and analysed using the method previously described. For each sample, three different analyses
499 were conducted and the average was taken as the corresponding data.
500
501
502

503 *In vitro dissolution studies*

504

505 Nine hundred ml of distilled water kept at $37 \pm 1^\circ\text{C}$ were used as dissolution medium and uniformity
506 conditions were ensured by an impeller (stirring rate 100 rpm). The determination of PZQ concentration was
507 performed by using a fiber optic apparatus (HELLMA, Milano, Italy) connected to a UV-spectrophotometer
508 (ZEISS, Germany) and managed with an user interface (Aspect Plus, Carl-Zeiss, Oberkochen, Germany).
509 Prior to analysis, the peak of the UV-wavelength absorbance of PZQ was identified at 217.10 nm. The
510 quantity of the sample to be introduced was calculated in order to achieve the sink conditions (with a total
511 concentration $\leq 0.20 \text{ Cs}$), resulting in 10 mg and the quantity of PZQ dissolved was assayed *in continuum* for
512 60 min (one scan for minute). Each sample was analyzed in triplicate and the resulted mean \pm SD was
513 considered as the final value.
514
515
516
517
518

519 *Determination of in vitro activity against adult Schistosoma mansoni*

520

521 In vitro studies were carried out in accordance with Swiss national and cantonal regulations on animal
522 welfare (permission no. 2070) at the Swiss Tropical and Public Health Institute (Basel, Switzerland). Female
523 mice (NMRI strain; weight $\sim 20\text{--}22 \text{ g}$) were purchased from Charles River (Germany), kept under
524 environmentally-controlled conditions (temperature $\sim 25^\circ\text{C}$; humidity $\sim 70\%$; 12-hour light and 12-hour dark
525
526
527
528
529
530
531

532
533
534 cycle) with free access to water and rodent diet and acclimatized for one week before infection. Cercariae of
535 Schistosoma mansoni were obtained from infected intermediate host snails (Biomphalaria glabrata).
536

537
538 For the in vitro studies adult schistosomes obtained via dissection from infected mice were incubated in the
539 presence of the test compounds at different concentrations (0.021-0.33 µg/ml) for up to 72 h. Phenotypes
540 were monitored at several time points based on motility, viability and morphological alterations under an
541 inverse microscope (Carl Zeiss, Germany, magnification 80x) [40]. Parasite viability values of treated and
542 untreated worms obtained from microscopic evaluation were averaged (means ± standard deviation) using
543 Microsoft Excel software. IC₅₀ values were calculated using CompuSyn software.
544
545
546

547 *Physical stability during storage and ulterior grinding*

548

549
550 In order to check possible modifications of solid state within time DSC analyses of Form C were repeated for
551 a period of 4 months. During storage time, the solid samples were stored in the dark in desiccators over
552 anhydrous calcium chloride at 25°C. Also, the stability of Form C upon grinding for additional 60 min at 25
553 Hz was tested by DSC and XRPD.
554
555
556
557

558 **RESULTS AND DISCUSSION**

559

560
561 The experimental design space nearby the milling conditions of formation of PZQ polymorph B was
562 examined with the help of a rotated Doehlert matrix to check the influence of operating parameters on the
563 solid state and median particle size of PZQ, when neat ground by its own. The 10 experiments were
564 performed in double (since the mills allows the set-up of two jars at the same time) varying time and
565 frequency of milling, following the randomized order proposed in Table 1. The experimental responses are
566 reported in Table 1, while a graphical illustration of the experimental design space, with the y₁ results in each
567 experimental point, is presented in Figure 2. Finally, a picture with y₂ results will be reported in Figure 5.
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590

591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649

Table 1. Doehlert design (2 factors) for neat grinding of PZQ: experimental domain, experimental plan, randomization and responses.

<i>Independent variables</i>		Lower level (coded -1)	Upper level (coded +1)					
Milling time (min)	x_1	180	300					
Milling frequency (Hz)	x_2	15	25					
<i>Dependent variables</i>								
PZQ crystal form*	y_1							
Median particle size (μm)**	y_2							
Drug recovery after milling (%)***	y_3							
Exp.	Random order	X_1	X_2	Milling time (min)	Milling frequency (Hz)	y_1	y_2 (μm) (mean \pm S.D)	y_3 (%) (mean \pm S.D.)
1	6	0.966	0.259	298	21	B	68.00 \pm 3.29	99.01 \pm 0.14
2	2	-0.966	-0.259	182	19	<i>B</i>	71.85 \pm 5.03	98.32 \pm 0.34
3	10	0.259	0.966	256	25	C	55.46 \pm 4.01	99.04 \pm 0.02
4	3	-0.259	-0.966	225	15	M	40.44 \pm 4.57	99.64 \pm 0.04
5	9	0.707	-0.707	282	16	M	47.19 \pm 3.09	99.32 \pm 0.16
6	4	-0.707	0.707	198	24	<i>C</i>	58.06 \pm 0.48	99.38 \pm 0.11
7	1	0.000	0.000	240	20	B	77.44 \pm 3.99	99.55 \pm 0.05
8	5	-0.433	-0.250	214	19	<i>C</i>	54.17 \pm 5.22	99.71 \pm 0.13
9	7	0.433	-0.250	266	19	M	40.80 \pm 0.34	99.16 \pm 0.23
10[§]	8	0.000	0.500	240	23	C	57.33\pm3.44	99.42\pm0.10

*characterized by XRPD analysis and confirmed by DSC and TGA analyses. Letters in italic font indicate a solid product with reduced crystallinity degree (corresponding to light colors in Figure 2). The presence of Form B is reported as *B*, Form C as *C*, while *M* correspond to mixtures of different crystalline forms and amorphous solid. ** determined by Laser Light Scattering; *** assessed by HPLC analysis; § process conditions taken as the standard ones for Form C




Figure 2. Distribution of the experiments in the rotated Doehlert design for two variables and different PZQ crystal forms obtained in each experimental point (y_1): Blue circles indicate Praziquantel Form B, Red circles Form C; light (blue and red) colors indicate a reduced crystallinity degree of Form B and C, respectively; Green circles designate miscellaneous of solid forms (mixture of amorphous and other crystal forms).

As clearly visible in Figure 2, it was possible to divide the 10 experiments in three groups, based on the solid state results (y_1). In the central zone of the hexagonal design space (EXP1, 2 and EXP 7 -central point of the design-) the presence of Form B, as the exclusive phase, with the characteristic XRPD pattern, endothermic peak at about 110 °C and absence of weight loss upon heating, was attested. Furthermore, in correspondence of EXP 3, 6, 8 and 10, mainly located in the upper part of the design space, a different XRPD pattern was found and a unique melting peak at about 106-107° C without water loss, suggesting the presence of another unknown anhydrous phase (later referred as Form C). Finally, in EXP 4, 5 and 9, placed in the lower zone of the experimental domain, mixtures of starting/amorphous/ hydrate/ polymorphic PZQ were obtained.

In Figure 3 three XRPD patterns, representative of each group, are proposed; besides the complete list of XRPD patterns is depicted in Figure S3a,b,c and main DSC/TGA data are reported in Table S1.




Figure 3 XRPD diffractograms representing the 3 solid states (y_1) found in the design space compared to commercial PZQ; arrows highlight peculiar signals of each solid form.

These results highlighted that PZQ solid state changes dramatically in response to little changes in time and frequency of milling. Indeed, as also showed in Figure 2, to reach a stable phase composition it is necessary a certain energy input. For example EXP 2, ground for a minor period of time, showed a reduced degree of crystallinity and lower reproducibility (of the results obtained from the two jars) than EXP 1 and 7 processed longer. Analogously, in the second set of experiments (Form C), EXP 6 and 8, performed using lower frequency and/or milling time, did not provide constant results and the melting enthalpy was generally lower (these experiments are indicated with lighter colors in Figure 2). Finally, the bottom of the experimental domain (corresponding to lower mechanical energy input) corresponded to uncomplete solid trasformations.

This set was in fact characterized by multiple coexisting phases: amorphous-nanocrystalline PZQ, traces of original PZQ (peculiar with respect to the other groups), hydrated phases (even small amounts of moisture in non-formally hydrated materials or in the laboratory environment can promote the formation of hydrate forms, as reported by several authors [41-44], and PZQ suffers from higroscopicity [45], and possibly an additional anhydrous polymorph not yet mentioned in the literature (having a weak melting endotherm at 98°C). As for this latter, given its limited concentration in the samples and the simultaneous presence of different solid phases herein, it was not possible to evince an exclusive pattern to distinguish an additional PZQ form. In addition, the weak endotherm may be also due to original PZQ form shifted to lower temperatures via the Gibbs-Thompson effect [46].

The measurement of powder temperature inside the jars in different milling conditions permitted to give additional explanations for the results of this explorative analysis for y_1 . Powder temperature inside the jars was continuously monitored (from 0 to 300 min) by means of special PMMA jars equipped by a temperature sensor. The results are shown in Figure 4. This was to check possible increase of temperature inside the jars (starting from a thermostated room temperature of 22°C), during the grinding process, since it is widely known that the impact and friction of the milling media with each others and the jars can induce an increase of powder temperature. The trend was the following: the temperature rapidly increased in the first 100 minutes of grinding, slowly reaching a plateau, even when milling for 5 hours. When grinding was performed at the highest frequency (25 Hz), the temperature reached after 180 minutes the maximum value of 39°C, and remained quite constant till the end of the process, while when grinding at 15 Hz the temperature never went beyond 33°C. These temperature data are in good agreement with the measurements performed with a thermocouple in the same vibrational mill [47] and by other authors [48]. As expected, the end temperatures detected in the jars made of zirconium oxide (having a different hardness and heat capacity in comparison to PMMA) and in the PMMA jar were different, being slightly higher those measured inside zirconia jars (in particular, after 5 h at at 25 Hz and 15 Hz the reached temperature was ranging about 44°C and 35°C, respectively). Nevertheless the PMMA jars were useful in that they provided a description of temperature progress over time, otherwise impossible in the conventional zirconium jars.




Figure 4. Temperature inside the jars during grinding at different frequencies measured using thermo jars (according to paragraph. 2.2.1.).

A comparison of these process temperatures and PZQ glass transition temperature permits to draw some remarks of this explorative analysis in relation to y_1 , remembering that amorphisation mainly occurs when milling is performed well below the glass transition temperature (T_g) of the system (the pure drug in this

827
828
829 case), while polymorphic transformations mainly occur when milling is carried out above [49]. As we
830 already reported [47], glass transition of melt-quenched PZQ is 37.70 °C. In a milling-induced amorphous
831 material, which might correspond to an enhanced molecular mobility, this value may decrease [22,50]. This
832 means that grinding at frequency 20-25 Hz permits to go well beyond T_g, whereas at 15 Hz powder
833 temperature is ranging about T_g. This gives reason of the polymorphic outcome at higher frequency of
834 milling (EXP 1, 3, 7, 10), where the temperature is around 40°C, and of the amorphous content detected in
835 powder samples processed at lower time of milling (corresponding to a temperature slightly lower than 40°C
836 EXP 2, 6, 8). This also explains the high variability of the powder processed at lower frequencies
837 (corresponding to EXP 9, 5, 4). In fact, in these experimental conditions, the powder temperature is in the
838 PZQ T_g range, thus the behavior of the system highly depends on the milling conditions, increasing the
839 uncertainty of the milling outcome [49].
840
841
842
843
844

845 **Median particle size of the ground products (y₂)**

846
847
848 As a second experimental response (y₂), the median particle size of the powder processed in different
849 operating conditions was evaluated by LLS, with the aim of further characterizing the solid products and of
850 searching for a possible correlation between the different forms obtained by milling and the powder particle
851 size. The median particle sizes of ground samples were comprised between 40 and 80 μm (as reported in
852 Table 1 and depicted in Figure 5), differently from raw PZQ, having a median size of 23.99 μm with a
853 slightly hinted bimodal shape distribution (see Figure S4 in Supplementary information). Even though a
854 precise division could not be based on the particle size distribution, a certain correlation between crystal
855 form and median particle size could be identified as following: the samples composed of Form B presented
856 the biggest sizes, ranging around a d(0.5) of 72 μm while in the case of polymorph C the d(0.5) was smaller
857 (around 56 μm). The lowest d(0.5) values were found in the case of the mixtures (around 42 μm). This was a
858 further confirmation that depending on the process conditions, in this design space, the obtained solid
859 products were divisible in three groups.
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885




Figure 5. $d(0.5)$ values and error bars ($n=3$) for the 10 ground samples (x axis reports the numbers of the experimental trial, blue circles indicate PZQ Form B, red circles Form C and green circles designate mixture of solid forms (mixture of amorphous and other crystal forms)).

Drug recovery after grinding PZQ by its own (y_3)

In the whole experimental domain, PZQ showed a degradation value of less than 1% with the only exception of EXP 2 ($1.68\% \pm 0.34$), as assessed by HPLC analysis and reported in Table 1 All ground samples were in accordance with the PZQ monograph in the Eur. Ph. (Ed. 8.0). This means that y_3 is almost constant in the studied design space and is not influenced by the variation of time and frequency of milling.

This also means that a high energy mechanical action (such as a protracted grinding for 182-298 min) on pure PZQ is capable of inducing changes in its physical state, either amorphisation or conversions between polymorphic crystalline forms, without producing significant chemical degradation. This is in contrast to its documented tendency to degrade when coground in presence of specific excipients [24,47,51]. In consideration of the different temperature detected in the jars (Figure 4) it is also evident that the heat is not the main responsible for drug degradation, in agreement to previous findings [47].

Evaluation of form C

The second part of this paper deals with the evaluation of Form C, which could be achieved in the conditions of EXP 3, 6, 8 and 10 of the experimental design. Nevertheless, the conditions of EXP 10 (240 min at 23 Hz) were taken as the standard ones, due to the highest crystallinity (see bold characters in Table 1). As anticipated in Table 1, in the case of for EXP 10 the drug recovery was of 99.42%.

At the DSC analysis, Form C shows the presence of a single well defined endotherm at 106.84 °C ($\Delta H=71.06$ J/g), clearly distinct from Form B and commercial PZQ (Figure 6). No other thermal event was observed in this DSC curve. Form C anhydrous nature was testified by the lack of weight loss in the TGA analysis (reported in Table S1).




Figure 6. DSC traces of Form C (red), B (blue) and commercial PZQ (black).

Form C exhibited some differences in the habitus morphology (Figure 7) comparing to Form B and raw PZQ: the particles were agglomerated in groups, without any sign of the needle-shape like of raw PZQ or little whiskers of Form B, previously reported [7]. As also evident from these images, and in agreement with previous LLS findings, the neat grinding of PZQ in these process conditions led to the formation of agglomerates having dimensions larger than commercial PZQ particles'.

1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062










Figure 7. ESEM images of Form C (EXP 10) [magnification 50X, 250 x, 500x, 1000x] compared to Scanning Electron Micrographs of Form B (EXP 7) [mag. 80x, 2200x in the frame] and commercial PZQ [mag. 151x, 2200x in the frame].

1063
1064
1065 The XRPD pattern of Form C, even if generally similar to Form B, was characterized by reflections at 6.98,
1066 8.55, 12.76, 13.96, 15.42, 16.52, 18.12, 19.82, 21.62, 22.57, 26.15, 27.65 and 28.92° of 2θ as reported in
1067 Figure 3 (see vertical dotted lines), which highlight the differences between the forms.
1068
1069

1070
1071 The crystal structure of Form C was solved from the synchrotron X-ray powder diffraction data, depicted in
1072 Figure 8. The cell was indexed using EXPO2014 [52] and TOPAS V5 [53] was used for the simulated
1073 annealing process, using Form B as the model. The annealing process led to a Rietveld refinement with Rwp
1074 of 2.5%, also shown in Figure 8. The resulting centrosymmetric monoclinic cell (reported in Figure 9) has
1075 space group *I*2/*c* and the following parameters: $a=22.02(2)$ Å, $b=5.910(1)$ Å, $c=26.980(2)$ Å, $\alpha=\gamma=90^\circ$, $\beta=$
1076 $109.765(4)^\circ$, density = 1.26 g/cm³ and volume 3304(2) Å³. All the diffraction patterns obtained from different
1077 Form C batches showed the same profile and no additional spurious peaks have been found. CCDC 1878799
1078 contains the supplementary crystallographic data for Form C. These data can be obtained free of charge from
1079 The Cambridge Crystallographic Data Centre via <https://www.ccdc.cam.ac.uk/structures>.
1080
1081
1082
1083
1084



1106
1107
1108
1109
1110 **Figure 8.** Rietveld refinement profile fit of Form C: in black the experimental pattern (collected using
1111 synchrotron radiation 0.700 Å), in red the calculated one. Residuals are displayed in blue and reflection ticks
1112 Atom: C....17 have been simulated from structure solution, and are reported in green.
1113
1114
1115
1116
1117
1118
1119
1120
1121




Figure 9. Capped stick representation of the proposed structure and crystal packing for Form C racemic mixture. The monoclinic centrosymmetric unit cell hosts 8 molecules, one crystallographically independent, in a $I2/c$ space group.

The cell has one crystallographically independent molecule in the asymmetric unit, as also confirmed in the ^{13}C CPMAS SSNMR spectrum (Figure 10) in which the differences between the packing of Form B and C are clearly visible. Even more evident the differences with commercial PZQ. In fact, similarly to Form B, in Form C only one set of resonances is visible, while raw PZQ is characterized by splitted signals, clearly evident in particular for the heterocyclic carbonyl at 164 ppm. The powder was also highly crystalline, as testified by very sharp peaks. ^{13}C chemical shift are listed in Table 2 with assignments and atom numbering in chemical structure of PZQ is reported in Figure 1.

1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239




Figure 10. (top) ^{13}C (100.65 MHz) CPMAS spectra with principal group assignments of commercial PZQ (a) Form B (b), Form C (c) recorded at 12 kHz; (bottom) ^{15}N (40.55 MHz) spectra of commercial PZQ (a) Form B (b), Form C (c) recorded at 9 KHz.


Table 2. Experimental and calculated ^{13}C and ^{15}N isotropic chemical shifts for the polymorph Form C of PZQ, with the corresponding assignments for each site in the asymmetric unit. The GIPAW-calculated chemical shielding are also reported.

Atom	Group	^{13}C		
		$\delta_{\text{iso}}(\text{exp}) / \text{ppm}$	$\delta_{\text{iso}}(\text{calc}) / \text{ppm}$	$\sigma_{\text{iso}} / \text{ppm}$
7'	C=O	173.3	173.8	-2.6
4	C=O	163.4	163.1	8.2
7a	C _q	135.1	137.8	33.4
11a	C _q	134	136.8	34.5
8	CH _(ar.)	129.1	131.0	40.2
11	CH _(ar.)	127.5	129.4	41.8
10	CH _(ar.)	127.1	128.5	42.8
9	CH _(ar.)	n.a. ^a	127.9	43.4
11b	CH _(aliph.)	55.5	56.1	115.1
3	CH ₂	50.1	49.3	121.9
1	CH ₂	45.5	43.8	127.5
1'	CH _(aliph.)	41.8	40.5	130.7
6	CH ₂	37.7	35.3	135.9
2'	CH ₂	29.6	28.1	143.1
7	CH ₂	29.1	27.4	143.8
6'	CH ₂	27.4	27.3	143.9
3'	CH ₂	26.8	25.5	145.7
4'5'	CH ₂	25.4	24.5	146.7
5'4'	CH ₂	n.a. ^a	23.4	147.9
^{15}N				
2	N	84.8	84.5	106.0
5	N	99.2	99.5	91.0


^aResonances are indistinguishable.

GIPAW-DFT calculations were performed on the proposed crystal structure of Form C. In particular, the geometry optimization was initiated from the structure determined from the XRPD pattern (376 atoms) and the refined structure was used for the chemical shift calculation. As reported in Figure 11 the geometry-

1299
1300
1301 optimized structure was almost completely superimposable with the one from the XRPD data and the
1302 simulated XRPD were identical (Figure 12).
1303
1304
1305
1306



1323
1324 **Figure 11.** Overlay of the crystal structure of the polymorph C of PZQ from XRPD data and its geometry-
1325 optimized crystal structure by DFT calculations (in green). An all-atom root-mean-square value of 0.176 Å
1326 was obtained by the comparison of the two crystal structures, using the software Mercury (CCDC, v3.10)
1327 [54]. The positions of the hydrogen atoms were ignored.
1328
1329



1348
1349 **Figure 12.** Comparison of the XRPD patterns of Form C crystal structure: in black, the simulation obtained
1350 from the DFT-optimized structure; in red, the simulated powder diffractogram of the Form C using the
1351 experimental crystal structure. Both simulations were carried out with Mercury by setting a wavelength of
1352 0.700Å.
1353
1354
1355
1356
1357

1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416

The calculated chemical shifts aided in assigning the resonances, and more importantly, they are a fundamental tool of the NMR crystallography approach since they provide correlation between the XRPD structure and the experimental one.[55-57] Indeed, we exploit them to reinforce the synchrotron XRPD data, by assessing whether the calculated ^{13}C , ^{15}N chemical shifts of the X-ray structure match the experimental ones that have been obtained from the above CPMAS experiments. Table 2 reports the assigned ^{13}C , ^{15}N resonances, as well as the corresponding calculated values. From the comparison of the experimental and computed ^{13}C chemical shifts, a root mean square deviation of 1.7 ppm is obtained. This overall value represents the agreement between the ^{13}C chemical shifts of the X-ray structure and those obtained experimentally. In an effort to rationalize this value, we note that Beran et al.[58] have recently assessed that GIPAW PBE ^{13}C chemical shifts can be calculated with a root mean square error of 2.2 ppm. Therefore, as our rmsd value is within this error, we can conclude that the X-ray determined structure correctly represent the crystal structure that corresponds to the SSNMR data. Finally, Figure 13 shows the graphical comparison between calculated and experimental ^{13}C chemical shifts: the data are linearly correlated with slope of 1.02 and a Pearson's correlation coefficient of 0.9996, thus demonstrating excellent agreement between calculation and experiment.





Figure 13. Plot of the GIPAW-calculated ^{13}C isotropic chemical shifts against the experimental ^{13}C isotropic chemical shifts. The line of best fit is $\delta_{\text{iso}}(\text{calc}) = 1.02[\delta_{\text{iso}}(\text{exp})] - 1.80$, and the Pearson's correlation coefficient is 0.9996.

1417
1418
1419 The crystal structure suggested a racemic nature for Form C, which was confirmed by polarimetric analysis,
1420 presenting an $[\alpha]$ of 0.0144 ± 0.0295 ($n=3$) and XRPD.
1421
1422

1423 The FT-IR spectrum of Form C, (Figure 14), was very similar to that of Form B, highlighting the close
1424 relationship between the polymorphs produced by neat grinding, while putting in light the differences with
1425 that of raw PZQ. In particular, for the region corresponding to the stretching of the carbonyl groups,
1426 indicated in the frame of Figure 14, also in the case of Form C, the conformers were in the *anti* position, as
1427 demonstrated by the lower frequency difference in $\nu(\text{CO})$ between the carbonyl groups (1642 and 1631
1428 cm^{-1}), whereas commercial PZQ showed the two signals at 1651 and 1626 cm^{-1} due to the *syn* conformation
1429 in accordance to previous literature [7, 59]. FT-IR spectroscopy was hence not useful for distinguishing
1430 between the two forms C and B, yet was helpful to discriminate easily both of them from commercial PZQ.
1431
1432
1433
1434


1435 In addition, this analysis was a suitable tool because it attested the identical conformation of the two
1436 polymorphic varieties formed by dry grinding. This confirmed PZQ conformational flexibility [23] and
1437 supported the idea that, also in the case of PZQ, dry milling allowed a polymorphic conversion via an
1438 amorphous intermediate. It is in fact reported that amorphous PZQ possesses as well an anti-conformation of
1439 the two carbonyl groups [60]. This assumption is also in agreement with the mechanism of phase transition
1440 during mechanochemical reactions proposed by Shakhshneider [61] and supported by several authors
1441 [42,43]. Moreover, it is worthy of note that even in a previous study of cocrystal formation by liquid assisted
1442 grinding, the PZQ isomer having anti orientation was shown to be preferred over the syn-isomer [23].
1443
1444
1445
1446
1447



1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
Figure 14. FT-IR spectra of the three PZQ polymorphic varieties

1470 The water saturation solubility at 20°C of Form C was assessed and compared to raw PZQ and Form B,
1471 resulting in the most soluble form with 382.69 ± 9.26 mg/L (mean \pm s.d.; $n=5$), while raw PZQ was $140.30 \pm$
1472
1473
1474
1475

1476
1477
1478 9.25 mg/L and Form B 281.31 ± 8.32 mg/L (figure 15) . In agreement with these findings, also the
1479
1480 dissolution performance of Form C at 37°C was better than raw PZQ, both in the entity and rate of
1481
1482 dissolution, reaching the 90% of drug dissolved in about 50 min..
1483
1484



1502
1503 **Figure 15.** Water saturation solubility at 20°C of the anhydrous forms of PZQ.
1504

1505 In vitro antischistosomal activity of Form C (against *Schistosoma Mansoni* adult) was then tested, resulting
1506 in an IC_{50} of 0.21464 μ M ($r= 0.97485$ μ M) after 72h, which is similar to PZQ's one (0.1. μ M) [62]. This
1507 testifies the maintaining of the Form C activity, even though the extensive grinding performed for its
1508 production. This fact also attests that the conformational polymorphism does not affect its activity, in a
1509 similar way to what has already been found in the case of form B [7].
1510
1511

1512
1513 Form C was unchanged for 2 months, while after three months it started to slowly recrystallize in PZQ
1514 commercial form (Figure 16), as visible from the weak endotherm detected at 135.81°C, with a downward
1515 shift due to the small crystallite size. This is quite typical of polymorphic forms produced by milling, which
1516 are almost always less stable than the starting (unmilled) form [22]. With respect to previously discovered
1517 Form B also produced by milling, which was stable for more than one year, the polymorph C is characterized
1518 by a dramatically lower physical stability. These findings are in agreement with its lowest melting point and
1519 highest water solubility among anhydrous PZQ polymorphs, and to the fact that metastable state generated
1520 by milling can recrystallize more or less rapidly upon storage.
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534




Figure 16. DSC curves of Form C on aging. From top to down: Fresh sample and samples after 1, 2, 3, 4 months.

When Form C was subjected to a further grinding for 60 min at 25 Hz, the DSC traces and XRPD pattern (Figure S5) also evidenced the formation of a certain amount of Form B in a sample mainly composed of Form C, still persistent. This means that, both on aging at ambient temperature (in a desiccator in the dark) and by milling again for further 60 min, the metastable form C converts into the most stable triclinic *P*-1 PZQ (CCDC 896767 [23]). Interestingly enough, the formation of Form B, which presumably is the metastable form closer to Form C according to Ostwal's rule of stages [63], is only possible by 4-5 h of milling only starting from commercial PZQ by non-interrupted continuous grinding. This confirms the general knowledge [22] that that milling process often induces a rich pattern of non-equilibrium transformations.

Conclusions

The performed work demonstrates that the application of DoE methodology in mechanochemistry is well suited for obtaining new polymorphic varieties, allowing the experimentalist to carefully consider every single factor affecting neat grinding reactions to drive the formation of the desired crystal form. Besides the

1594
1595
1596 monitoring of the temperature inside the milling jars is an useful tool to understand and predict the end point
1597 of mechanochemical reactions. The new praziquantel polymorphic variety, Form C, found during the
1598 explorative analysis, represents the third anhydrous crystal of this drug. It can be obtained by neat grinding
1599 of the drug by its own, without any solvent addition, and it is otherwise inaccessible by conventional crystal
1600 engineering methods. The multidisciplinary approach applied for its characterization has permitted to
1601 successfully solve its crystal structure from Synchrotron XRPD, to propose a mechanism of formation
1602 induced by mechanochemical conditions and to highlight the strengths and weaknesses of the Form C of
1603 Praziquantel, the drug of choice for the Schistosomiasis treatment.
1604
1605
1606
1607

1608 **Aknowledgements**

1609 This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-
1610 profit sectors. PCV thanks Dr. G. Mollica for valuable discussion on GIPAW-DFT calculations. BP thanks
1611 Alice Cerniz and Anna Candido for preparation of the samples.
1612
1613
1614

1615 **Supporting information**

1616 Plot of the experimental ¹³C and ¹⁵N chemical shifts against the GIPAW-calculated ¹³C and ¹⁵N chemical
1617 shieldings (σ_{iso}), respectively; XRPD patterns and DSC/TGA data of all samples included in the explored
1618 experimental domain; particle size distribution of commercial PZQ; physical stability of Form C upon
1619 milling.
1620
1621
1622
1623

1624 Crystallographic information file (CIF) for Form C, embedding the measured and calculated profiles.
1625 (Structure factors are available from CCDC - CCDC 1878799).
1626
1627
1628

1629 **Conflict of interest**

1630 The authors there are no conflicts of interest associated with this publication and there has been no
1631 significant financial support for this work that could have influenced its outcome.
1632
1633
1634

1635 **References**

- 1636
1637 [1] D.G. Colley, A L Bustinduy, WE Secor, C H King, Human schistosomiasis, *Lancet* 383 (2014)
1638 2253-64. doi: 10.1016/S0140-6736(13)61949-2.
1639
1640 [2] M. Lindenberg, S. Kopp, J.B. Dressman, Classification of orally administered drugs on the World
1641 Health Organization Model list of Essential Medicines according to the biopharmaceutics
1642 classification system. *Eur J Pharm Biopharm* 58 (2004) 265-278. doi: 10.1016/j.ejpb.2004.03.001
1643
1644 [3] N. Passerini, B. Albertini, B. Perissutti, L. Rodriguez, Evaluation of melt granulation and ultrasonic
1645 spray congealing as techniques to enhance the dissolution of praziquantel, *Int J Pharm* 318 (2006)
1646 92-102. 10.1016/j.ijpharm.2006.03.028
1647
1648
1649
1650
1651
1652

- 1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
- [4] D.P. McManus, D.W. Dunne, M. Sacko, J. Utzinger, B.J. Vennervald, X.-N. Zhou, Schistosomiasis. *Nat. Rev. Dis. Primers* 4 (2018):13-. doi: 10.1038/s41572-018-0013-8
- [5] D Cioli, L. Pica-Mattocchia, Praziquantel, *Parasitol. Res.* 90 Supp 1(2003) S3-9. doi: 10.1007/s00436-002-0751-z
- [6] J.T. Coulibaly, G. Panic, K.D. Silue, J. Kovac, J. Hattendorf, J. Keiser. Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with *Schistosoma mansoni*: a randomised controlled, parallel-group, dose-ranging, phase 2 trial, *Lancet Glob Health.* 5 (7) (2017) e688-e698. doi: 10.1016/S2214-109X(17)30187-0.
- [7] D. Zanolla, B. Perissutti, N. Passerini, M.R. Chierotti, D. Hasa, D. Voinovich, L. Gigli, N. Demitri, S. Geremia, J. Keiser, P. Cerreia Vioglio, B. Albertini, A new soluble and bioactive polymorph of praziquantel, *Eur J Pharm and Biopharm,* 127 (2018) 19-28. doi: 10.1016/j.ejpb.2018.01.018
- [8] C.R. Groom, I.J. Bruno, M.P. Lightfoot, S.C. Ward, The Cambridge Structural Database. *Acta Crystallogr B Struct Sci Cryst Eng Mater* 72 (2016)171-179. doi: 10.1107/S2052520616003954.
- [9] F C. Lombardo, B.Perissutti, J. Keiser, Activity and pharmacokinetics of a praziquantel crystalline polymorph in the *Schistosoma mansoni* mouse model, submitted (20th February 2019).
- [10] D. H. Doehlert, Uniform Shell Designs, *Applied Statistics* 19(3) (1970) 231-239. doi: 10.2307/2346327.
- [11] G. Lewis, D. Mathieu, R. Phan-tan-luu, *Pharmaceutical Experimental Design*, CRC PRes, Marcel Dekker, New York, 1999, pp.221-235. doi:10.1201/9780203508688.
- [12] T. Lundstedt, E. Seifert, L. Abramo, B. Thelin, A. Nyström, J. Pettersen, R. Bergman, Experimental design and optimization, *Chemometrics and Intelligent Laboratory Systems* 42 (1998), pp. 3–40. doi: 10.1016/S0169-7439(98)00065-3
- [13] S.L.C Ferreira, W N L dos Santos, CM Quintella, BB Neto, JM Bosque-Sendra, Doehlert matrix: a chemometric tool for analytical chemistry—review, *Talanta* 63 (4) 2004, 1061-1067. doi: 10.1016/j.talanta.2004.01.015.
- [14] S.L.C. Ferreira, R.E. Bruns, E.G.P. da Silva, W.N.L. dos Santos, C.M. Quintella, J.M. David, J.B. de Andrade, M.C. Breitkreitz, I.C.S.F. Jardim, B.B. Neto, Statistical designs and response surface techniques for the optimization of chromatographic systems, *J Chrom A,* 1158 (1-2) (2007) 2-14. DOI: 10.1016/j.chroma.2007.03.051

- 1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
- [15] M A Bezerra, R.E. Santelli, E.P. Oliveira, L.S. Villar, L.A. Escaleira, Response surface methodology (RSM) as a tool for optimization in analytical chemistry. *TALANTA* 76 (2008) 965-977. doi: 10.1016/j.talanta.2008.05.019. Epub 2008 May 21.
- [16] D. Vojnovic, P. Rupena, M. Moneghini, F. Rubessa, S. Coslovich, R. Phan-Tan-Luu, R.M. Sergent, Experimental research methodology applied to wet pelletization in a high shear mixer. Part I, *S.T.P., Pharma Sci.* 3 (1993) 130–135.
- [17] D. Vojnovic, D. Chicco, H. El Zenary, Doehlert experimental design applied to optimization and quality control of a granulation process in a high shear mixer, *Int. J. Pharm.* 145 (1996) 203-213. doi: 10.1016/S0378-5173(96)04771-0 10.1016/S0378-5173(96)04771-0
- [18] D. Voinovich, M. Moneghini, B.Perissutti, J. Filipovic-Grcic, I. Grabnar, Preparation in high-shear mixer of sustained-release pellets by melt pelletisation, *Int. J. Pharm.* 203 (2000) 235. doi: 10.1016/S0378-5173(00)00455-5
- [19] S. Thirunahari, P.S. Chow, R.B.H. Tan, Quality by design (QbD)-based crystallization process development for the polymorphic drug tolbutamide, *Cryst Growth Des* 11 (7) (2011), 3027-3038. doi: 10.1021/cg2003029
- [20] D. Hasa, B. Perissutti, C. Cepek, S. Bhardwaj, E. Carlino, M. Grassi, S. Invernizzi, D. Voinovich, Drug salt formation via mechanochemistry: The case study of vincamine, *Mol. Pharmaceutics*, 10 (1) (2013), 211-224. DOI: 10.1021/mp300371f.
- [21] K. Nagapudi, E.Y. Umanzor, C. Masui, High-throughput screening and scale-up of cocrystals using resonant acoustic mixing, *Int J Pharm.* 521 (1-2) (2017), 337-345. doi: 10.1016/j.ijpharm.2017.02.027
- [22] A. De Gusseme, C Neves, JF Willart, A Rameau, M Descamps, Ordering and disordering of molecular solids upon mechanical milling: the case of fananserine, *J Pharm. Sci.* 97 (11) (2008) 5000-12. doi: 10.1002/jps.21472.
- [23] J. C. Espinosa-Lara, D. Guzman-Villanueva, J. I. Arenas-García, D.Herrera-Ruiz, J. Rivera-Islas, P. Román-Bravo, H. Morales-Rojas, H. Höpfl, Cocrystals of Active Pharmaceutical Ingredients Praziquantel in Combination with Oxalic, Malonic, Succinic, Maleic, Fumaric, Glutaric, Adipic, And Pimelic Acids. *Cryst. Growth Des.* 13 (2013), 169–185. doi: 10.1021/cg301314w
- [24] B. Perissutti, N. Passerini, R. Trastullo, J. Keiser, D. Zanolla, G. Zingone, D. Voinovich, B. Albertini, An explorative analysis of process and formulation variables affecting comilling in a vibrational mill: The case of praziquantel, *Int J Pharm.* 533 (2) (2017) 402-412. doi: 10.1016/j.ijpharm.2017.05.053

1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829

- [25] D. Mathieu, J. Nony, R. Phan-Tan-Luu, New Efficient Technology for Research using Optimal Desing (NEMRODW), software L.P.R.A.I., Marseille (2011).
- [26] Y. Sun, S. J. Bu, Simple, cheap and effective high-performance liquid chromatographic method for determination of praziquantel in bovine muscle, *J. Chromatogr. B* 899 (2012), 160–162. doi: 10.1016/j.jchromb.2012.05.004
- [27] A. Cedillo-Cruz, M. I. Aguilar, M. Flores-Alamo, F. Palomares-Alonso, H. Jung-Cook, A straightforward and efficient synthesis of praziquantel enantiomers and their 40-hydroxy derivatives. *Tetrahedron: Asymmetry* 25 (2014), 133–140.
- [28] P. Roszkowski, J. K. Maurin, Z. Czarnocki, Enantioselective synthesis of (R)-(-)-praziquantel (PZQ), *Tetrahedron: Asymmetry* 17 (9) (2006), 1415-1419. doi: 10.1016/j.tetasy.2006.04.023
- [29] A. Lausi, M. Polentarutti, S. Onesti, J. R. Plaisier, E. Busetto, G. Bais, L. Barba, A. Cassetta, G. Campi, D. Lamba, A. Pifferi, S.C. Mande, D.D. Sarma, S.M. Sharma, G. Paolucci, Status of the crystallography beamlines at Elettra, *The European Physical Journal Plus*, 130 (3) (2015), 1-8. doi: 10.1140/epjp/i2015-15043-3.
- [30] A.P. Hammersley, S.O. Svensson, M. Hanfland, A. N. Fitch, and D. Häusermann, Two-Dimensional Detector Software: From Real Detector to Idealised Image or Two-Theta Scan, *High Pressure Research* 14 (1996) 235-248. doi: 10.1080/08957959608201408
- [31] A P. Hammersley, ESRF Internal Report, ESRF98HA01T, FIT2D V9.129 Reference Manual V3.1 (1998)
- [32] S. J. Clark, M. D. Segall, C. J. Pickard, P. J. Hasnip, M. J Probert, K.Refsn, M. C. Payne, First principles methods using CASTEP, *Z. Kristallogr.* 220 (2005), 567–570. doi: 10.1524/zkri.220.5.567.65075
- [33] P. J. Hasnip, K. Refson, M. I. J. Probert, J. R. Yates, S. J. Clark, C. J. Pickard, Density functional theory in the solid state, *Philos. Trans. R. Soc. A-Math. Phys. Eng. Sci.* 372 (2014) 20130270. doi: 10.1098/rsta.2013.0270
- [34] C. J. Pickard and F.Mauri, All-electron magnetic response with pseudopotentials: NMR chemical shifts, *Phys. Rev. B* 63 (2001), 245101. doi: 10.1103/PhysRevB.63.245101
- [35] J. P. Perdew, K. Burke, M. Ernzerhof, Generalized Gradient Approximation Made Simple, *Phys. Rev. Lett.* 1996, 77, 3865–3868. Erratum *Phys. Rev. Lett.* 78, 1396 (1997) doi: 10.1103/PhysRevLett.77.3865.

- 1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
- [36] E. R. McNellis, J. Meyer and K. Reuter, Azobenzene at coinage metal surfaces: Role of dispersive van der Waals interactions, *Phys. Rev. B*, 80 (2009), 205414. doi: 10.1103/PhysRevB.80.205414
- [37] A. Tkatchenko and M. Scheffler, Accurate Molecular Van Der Waals Interactions from Ground-State Electron Density and Free-Atom Reference Data, *Phys. Rev. Lett.* 102 (2009) 73005. doi: 10.1103/PhysRevLett.102.073005
- [38] R. K. Harris, P. Hodgkinson, C. J. Pickard, J. R. Yates, V. Zorin, Chemical shift computations on a crystallographic basis: some reflections and comments, *Magn. Reson. Chem.*, 45 (2007), S174–S186. doi: 10.1002/mrc.2132.
- [39] G.N.M. Reddy, D. S. Cook, D. Iuga, R.I. Walton, A. Marsh, S.P. Brown, Co-existence of Distinct Supramolecular Assemblies in Solution and in the Solid State, *Solid State Nucl. Magn. Reson.*, 65 (2015) 41–48. doi: 10.1002/chem.201604832
- [40] F C. Lombardo, V Pasche, G Panic, Y Endriss, J. Keiser, Life cycle maintenance and drug-sensitivity assays for early drug discovery in *Schistosoma mansoni*, *Nature Protocols* 14 (2019) 461–481. doi: 10.1038/s41596-018-0101-y
- [41] S. L. James, C.J. Adams, C. Bolm, D. Braga, P Collier, T Friščić, F Grepioni, K. D. M. Harris, G. Hyett, W. Jones, A Krebs, J Mack, L Maini, A. Guy Orpen, I P. Parkin, W. C. Shearouse, J W. Steedk, D. C. Waddelli, Mechanochemistry: opportunities for new and cleaner synthesis, *Chem. Soc. Rev.* 41 (2012), 413–447. doi: 10.1039/c1cs15171a
- [42] W. Jones and M.D.Eddleston, Introductory lecture: Mechanochemistry, a versatile synthesis strategy for new materials. *Faraday Discuss.* 170 (2014), 9-34. doi:10.1039/C4FD00162A
- [43] A.M. Belenguer, G.I. Lampronti, J. K M.. Sander, Reliable Mechanochemistry: Protocols for Reproducible Outcomes of Neat and Liquid Assisted Ball-mill Grinding Experiments. *J. Vis. Exp.* 131 (2018), e56824, doi:10.3791/56824
- [44] I. A. Tumanov, A. A. L. Michalchuk, A.A. Politov, E.V. Boldyreva, V.V. Boldyrev, Inadvertent liquid assisted grinding: a key to “dry” organic mechano-co-crystallisation? *CrystEngComm*, 19 (2017) 2830-2835. doi: 10.1039/C7CE00517B (Communication).
- [45] Biltricide data sheet. url:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018714s013lbl.pdf.
- [46] D. Hasa, D. Voinovich, B. Perissutti, G. Grassi, S. Fiorentino, R. Farra, M. Abrami, I. Colombo, M. Grassi, Reduction of melting temperature and enthalpy of drug crystals: Theoretical aspects, *Eur J Pharm Sci* 50.1 (2013), 17–28. DOI: 10.1016/j.ejps.2013.03.018

- 1889
1890
1891 [47] D. Zanolla, B. Perissutti, N. Passerini, S. Invernizzi, D. Voinovich, S. Bertoni, C. Melegari, G.
1892 Millotti, B. Albertini, Milling and comilling Praziquantel at cryogenic and room temperatures:
1893 Assessment of the process-induced effects on drug properties, *J Pharm Biomed Anal.* 153(2018),
1894 82-89. 10.1016/j.jpba.2018.02.018
1895
1896
1897
1898 [48] N. Chieng, Z. Zujovic, G. Bowmaker, T. Rades, D. Saville, Effect of milling on the solid-state
1899 conversion of ranitidine hydrochloride form 1, *Int. J. Pharm.* 327 (2006) 36-44. doi:
1900 10.1016/j.ijpharm.2006.07.032
1901
1902
1903 [49] M. Descamps, J.F. Willart, E. Dudognon, V. Caron, Transformation of pharmaceutical compounds
1904 upon milling and comilling: The role of Tg, *J. Pharm. Sci.* 96 (5) (2007) 1398–1407. doi:
1905 10.1002/jps.20939.
1906
1907
1908 [50] B. Schammé, X. Monnier, N. Couvrat, L. Delbreilh, V. Dupray, E. Dargent, G. Coquerel, Insights on
1909 the Physical State Reached by an Active Pharmaceutical Ingredient upon High-Energy Milling, *J.*
1910 *Phys. Chem. B* 121 (2017), 5142–5150. doi: 10.1021/acs.jpcc.7b02247.
1911
1912
1913 [51] I. Šagud, D. Zanolla, B. Perissutti, N. Passerini, I. Škorić, Identification of degradation products of
1914 praziquantel during the mechanochemical activation, *J Pharm Biomed Anal.* 159 (2018), 291-295.
1915 DOI: 10.1016/j.jpba.2018.07.002
1916
1917
1918 [52] A. Altomare, C. Cuocci, C. Giacobazzo, A. Moliterni, R. Rizzi, N. Corriero, A. Falcicchio, EXPO2014.
1919 A kit of tools for phasing crystal structures solution by powder diffraction data, *J. Appl. Cryst.* 46
1920 (2013), 1231-1235. doi:10.1107/S0021889813013113
1921
1922
1923 [53] A. L. Spek, Structure validation in chemical crystallography. *Acta Cryst. D*65 (2) (2009), 148-155.
1924 doi: 10.1107/S090744490804362X
1925
1926
1927 [54] F. Macrae, I. J. Bruno, J. A. Chisholm, P.R. Edgington, P. McCabe, E. Pidcock, L. Rodriguez-
1928 Monge, R. Taylor, J. van de Streek, P.A. Wood, Mercury CSD 2.0 - New Features for the
1929 Visualization and Investigation of Crystal Structures, *J. Appl. Cryst.*, 41 (2008), 466-470. doi:
1930 10.1107/S0021889807067908
1931
1932
1933 [55] P. Cerreia Vioglio, L. Catalano, V. Vasylyeva, C. Nervi, M.R. Chierotti, G. Resnati, R. Gobetto, P.
1934 Metrangolo, Natural Abundance ¹⁵N and ¹³C Solid-State NMR Chemical Shifts: High Sensitivity
1935 Probes of the Halogen Bond Geometry, *Chemistry* 22 (47) (2016), 16819-16828. doi:
1936 10.1002/chem.201603392
1937
1938
1939 [56] S.D. Gumbert, M. Körbitzer, E. Alig, E., M.U. Schmidt, M.R. Chierotti, R. Gobetto, X. Li, J. Van De
1940 Streek, Crystal structure and tautomerism of Pigment Yellow 138 determined by X-ray powder
1941
1942
1943
1944
1945
1946
1947

1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006

diffraction and solid-state NMR, *Dyes and Pigments* 131(2016) 364-372. doi:
10.1016/j.dyepig.2016.03.035

- [57] F. Rossi, P. Cerreia Vioglio, S. Bordignon, V. Giorgio, C. Nervi, E. Priola, R. Gobetto, K. Yazawa, M.R. Chierotti, Unraveling the Hydrogen Bond Network in a Theophylline-Pyridoxine Salt Cocrystal by a Combined X-ray Diffraction, Solid-State NMR, and Computational Approach, *Cryst. Growth Des.* 18 (4) (2018), 2225-2233. doi: 10.1021/acs.cgd.7b01662
- [58] J.D. Hartman, R.A. Kudla, G.M. Day, L.J. Mueller, G.J.O. Beran, Benchmark fragment-based ¹H, ¹³C, ¹⁵N and ¹⁷O chemical shift predictions in molecular crystals, *Phys Chem Chem Phys.* 18(31) (2016) 21686–21709. doi: 10.1039/c6cp01831a
- [59] A. Borrego-Sánchez, C. Viseras, C. Aguzzi, C.I. Sainz-Díaz, Molecular and crystal structure of praziquantel. Spectroscopic properties and crystal polymorphism. *Eur J Pharm Sci* 92 (2016), 266–275. Doi: 10.1016/j.ejps.2016.04.023
- [60] E.C. Arrúa, M.J.G. Ferreira, C.J. Salomon, T.G. Nunes, Elucidating the guest-host interactions and complex formation of praziquantel and cyclodextrin derivatives by ¹³C and ¹⁵N solid-state NMR spectroscopy, *Int J Pharm* 496 (2015) 812–821. doi: 10.1016/j.ijpharm.2015.11.026
- [61] T. P. Shakhtshneider, Phase transformations and stabilization of metastable states of molecular crystals under mechanical activation, *Solid State Ionics* 101–103 (1997), 851–856. doi: 10.1016/S0167-2738(97)00224-5
- [62] G. Mayoka, J. Keiser, G. Haeberli, K. Chibale, Structure–Activity Relationship and in Vitro Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Studies of N-aryl 3-Trifluoromethyl Pyrido[1,2-a]benzimidazoles That Are Efficacious in a Mouse Model of Schistosomiasis, *ACS Infect Dis.* 2018 Dec 23. doi: 10.1021/acsinfecdis.8b00313.
- [63] W. Ostwald, Studien über die Bildung und umwandlung fester Körper, *Zeitschrift für Physik.* 22 (1897), 289-330.

Figure legends

Figure 1. Chemical structure of Praziquantel (PZQ) with atom numbering.

Figure 2. Distribution of the experiments in the rotated Doehlert design for two variables and different PZQ crystal forms obtained in each experimental point (y_1): Blue circles indicate Praziquantel Form B, Red circles Form C; light (blue and red) colors indicate a reduced crystallinity degree of Form B and C, respectively; Green circles designate miscellaneous of solid forms (mixture of amorphous and other crystal forms).

Figure 3 XRPD diffractograms representing the 3 solid states (y_1) found in the design space compared to commercial PZQ; arrows highlight peculiar signals of each solid form.

Figure 4. Temperature inside the jars during grinding at different frequencies measured using thermojars (according to paragraph. 2.2.1.).

Figure 5. $d(0.5)$ values and error bars ($n=3$) for the 10 ground samples (x axis reports the numbers of the experimental trial, blue circles indicate PZQ Form B, red circles Form C and green circles designate mixture of solid forms (mixture of amorphous and other crystal forms)).

Figure 6. DSC traces of Form C (red), B (blue) and commercial PZQ (black).

Figure 7. ESEM images of Form C (EXP 10) [magnification 50X, 250x, 500x, 1000x] compared to Scanning Electron Micrographs of Form B (EXP 7) [mag. 80x, 2200x in the frame] and commercial PZQ [mag. 151x, 2200x in the frame].

Figure 8. Rietveld refinement profile fit of Form C: in black the experimental pattern (collected using synchrotron radiation 0.700 \AA), in red the calculated one. Residuals are displayed in blue and reflection ticks Atom: C 17 have been simulated from structure solution, and are reported in green.

Figure 9. Capped stick representation of the proposed structure and crystal packing for Form C racemic mixture. The monoclinic centrosymmetric unit cell hosts 8 molecules, one crystallographically independent, in a $I2/c$ space group.

Figure 10. (top) ^{13}C (100.65 MHz) CPMAS spectra with principal group assignments of commercial PZQ (a) Form B (b), Form C (c) recorded at 12 kHz; (bottom) ^{15}N (40.55 MHz) spectra of commercial PZQ (a) Form B (b), Form C (c) recorded at 9 KHz.

Figure 11. Overlay of the crystal structure of the polymorph C of PZQ from XRPD data and its geometry-optimized crystal structure by DFT calculations (in green). An all-atom root-mean-square value of 0.176 \AA was obtained by the comparison of the two crystal structures, using the software Mercury (CCDC, v3.10) (Macrae et al., 2008). The positions of the hydrogen atoms were ignored.


Figure 12. Comparison of the XRPD patterns of Form C crystal structure: in black, the simulation obtained from the DFT-optimized structure; in red, the simulated powder diffractogram of the Form C using the experimental crystal structure. Both simulations were carried out with Mercury by setting a wavelength of 0.700 \AA .

Figure 13. Plot of the GIPAW-calculated ^{13}C isotropic chemical shifts against the experimental ^{13}C isotropic chemical shifts. The line of best fit is $\delta_{\text{iso}}(\text{calc}) = 1.02[\delta_{\text{iso}}(\text{exp})] - 1.80$, and the Pearson's correlation coefficient is 0.9996.


Figure 14. FT-IR spectra of the three PZQ polymorphic varieties

Figure 15. Water solubility at 20°C of the anhydrous forms of PZQ.

Figure 16. DSC curves of Form C on aging. From top to down: Fresh sample and samples after 1, 2, 3, 4 months.





Frequency (Hz)





Time (min)







Counts





















N2


N5


c)


b)


a)

















Supplementary information




Figure S1. Plot of the experimental ^{13}C chemical shifts against the GIPAW-calculated ^{13}C chemical shieldings (σ_{iso}) to determine σ_{ref} . The slope of the line of best fit was constrained to -1 , which gives an intercept of 171.2 ± 0.4 ppm. The Pearson's correlation coefficient is 0.9991.




Figure S2. Plot of the experimental ^{15}N chemical shifts against the GIPAW-calculated ^{15}N chemical shieldings (σ_{iso}) to determine σ_{ref} . The slope of the line of best fit was constrained to -1 , which gives an intercept of 190.5 ± 0.3 ppm. The Pearson's correlation coefficient is 0.9980.




Figure S3a: XRPD patterns of the EXP 1, 2, 7 compared to raw PZQ and Form B.




Figure S3b: XRPD patterns of the EXP 3, 6, 8, 10 (Form C), compared to raw PZQ and Form B.




Figure S3c: XRPD patterns of the EXP 4, 5, 9 compared to raw PZQ and Form B and EXP 10 (Form C)

Table S1 : Averaged Results of DSC and TGA analyses of the 10 samples produced in different milling conditions, according to the Doehlert matrix.

EXP	ΔH endothermal event (J/g)	Peak temperature (°C)	Weight loss (%)	Dehydration temperature (°C)
1	62.58	110.51	0.00	-
2	36.39	109.60	0.00	-
3	74.92	106.50	0.00	-
4	4.94	98.62	0.00	-
5	86.88	132.81	1.35	70
	15.05	70.27		
	60.59	109.61		
6	8.29	136.76	0.00	-
	88.78	134.16		
	63.91	110.34		
7	55.64	106.51	0.00	-
8	13.05	74.73	1.35	70
	56.54	111.89		




Figure S4. Particle size distribution of raw PZQ




Figure S5. Physical stability of Form C upon milling (60 min at 25 Hz): PXRD pattern (left), and DSC curves (right) of: fresh sample (bottom) and ground sample (up).

Table 1. Doehlert design (2 factors) for neat grinding of PZQ: experimental domain, experimental plan, randomization and responses.

<i>Independent variables</i>				Lower level (coded -1)	Upper level (coded +1)			
Milling time (min)	x_1			180	300			
Milling frequency (Hz)	x_2			15	25			
<i>Dependent variables</i>								
PZQ crystal form*	y_1							
Median particle size (μm)**	y_2							
Drug recovery after milling (%)***	y_3							
Exp.	Random order	X_1	X_2	Milling time (min)	Milling frequency (Hz)	y_1	y_2 (μm) (mean \pm S.D.)	y_3 (%) (mean \pm S.D.)
1	6	0.966	0.259	298	21	B	68.00 \pm 3.29	99.01 \pm 0.14
2	2	-0.966	-0.259	182	19	<i>B</i>	71.85 \pm 5.03	98.32 \pm 0.34
3	10	0.259	0.966	256	25	C	55.46 \pm 4.01	99.04 \pm 0.02
4	3	-0.259	-0.966	225	15	M	40.44 \pm 4.57	99.64 \pm 0.04
5	9	0.707	-0.707	282	16	M	47.19 \pm 3.09	99.32 \pm 0.16
6	4	-0.707	0.707	198	24	<i>C</i>	58.06 \pm 0.48	99.38 \pm 0.11
7	1	0.000	0.000	240	20	B	77.44 \pm 3.99	99.55 \pm 0.05
8	5	-0.433	-0.250	214	19	<i>C</i>	54.17 \pm 5.22	99.71 \pm 0.13
9	7	0.433	-0.250	266	19	M	40.80 \pm 0.34	99.16 \pm 0.23
10[§]	8	0.000	0.500	240	23	C	57.33\pm3.44	99.42\pm0.10

*characterized by XRPD analysis and confirmed by DSC and TGA analyses. Letters in italic font indicate a solid product with reduced crystallinity degree (corresponding to light colors in Figure 2). The presence of Form B is reported as *B*, Form C as *C*, while *M* correspond to mixtures of different crystalline forms and amorphous solid. ** determined by Laser Light Scattering; *** assessed by HPLC analysis; § process conditions taken as the standard ones for Form C

Table 2. Experimental and calculated ^{13}C and ^{15}N isotropic chemical shifts for the polymorph Form C of PZQ, with the corresponding assignments for each site in the asymmetric unit. The GIPAW-calculated chemical shielding are also reported.

Atom	Group	^{13}C		
		$\delta_{\text{iso}}(\text{exp}) / \text{ppm}$	$\delta_{\text{iso}}(\text{calc}) / \text{ppm}$	$\sigma_{\text{iso}} / \text{ppm}$
7'	C=O	173.3	173.8	-2.6
4	C=O	163.4	163.1	8.2
7a	C _q	135.1	137.8	33.4
11a	C _q	134	136.8	34.5
8	CH _(ar.)	129.1	131.0	40.2
11	CH _(ar.)	127.5	129.4	41.8
10	CH _(ar.)	127.1	128.5	42.8
9	CH _(ar.)	n.a. ^a	127.9	43.4
11b	CH _(aliph.)	55.5	56.1	115.1
3	CH ₂	50.1	49.3	121.9
1	CH ₂	45.5	43.8	127.5
1'	CH _(aliph.)	41.8	40.5	130.7
6	CH ₂	37.7	35.3	135.9
2'	CH ₂	29.6	28.1	143.1
7	CH ₂	29.1	27.4	143.8
6'	CH ₂	27.4	27.3	143.9
3'	CH ₂	26.8	25.5	145.7
4'5'	CH ₂	25.4	24.5	146.7
5'4'	CH ₂	n.a. ^a	23.4	147.9
^{15}N				
2	N	84.8	84.5	106.0
5	N	99.2	99.5	91.0

^aResonances are indistinguishable.

checkCIF/PLATON report

Structure factors have been supplied for datablock(s) PZQFormC

THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED CRYSTALLOGRAPHIC REFEREE.

No syntax errors found. CIF dictionary Interpreting this report

Datablock: PZQFormC

Bond precision: C-C = 0.0122 Å Wavelength=0.70000
Cell: a=22.017(15) b=5.910(1) c=26.980(2)
 alpha=90 beta=109.765(4) gamma=90
Temperature: 298 K

	Calculated	Reported
Volume	3304(2)	3304(2)
Space group	I 2/c	I2/c
Hall group	-I 2yc	-I 2xc
Moiety formula	C19 H24 N2 O2	C19 H24 N2 O2
Sum formula	C19 H24 N2 O2	C19 H24 N2 O2
Mr	312.40	312.40
Dx,g cm ⁻³	1.256	1.256
Z	8	8
Mu (mm ⁻¹)	0.078	0.075
F000	1344.0	336.0
F000'	1344.49	
h,k,lmax	10,2,13	
Nref	208	
Tmin,Tmax		
Tmin'		

Correction method= Not given

Data completeness= 0.000 Theta(max)=

R(reflections)= wR2(reflections)=

S = Npar=

The following ALERTS were generated. Each ALERT has the format
test-name_ALERT_alert-type_alert-level.
Click on the hyperlinks for more details of the test.

Alert level B

PLAT340_ALERT_3_B Low Bond Precision on C-C Bonds 0.01219 Ang.

Alert level C

REFI015_ALERT_1_C _refine_ls_shift/su_max is missing
Maximum shift/s.u. ratio after final refinement cycle.
The following tests will not be performed
SHFSU_01

THETM01_ALERT_3_C The value of sine(theta_max)/wavelength is less than 0.500
Calculated sin(theta_max)/wavelength = 0.4886

PLAT127_ALERT_1_C Implicit Hall Symbol Inconsistent with Explicit -I 2xc

PLAT410_ALERT_2_C Short Intra H...H Contact H11 ..H13 . 1.94 Ang.
x,y,z = 1_555 Check

Alert level G

ABSMU01_ALERT_1_G Calculation of _exptl_absorpt_correction_mu
not performed for this radiation type.

PLAT092_ALERT_4_G Check: Wavelength Given is not Cu,Ga,Mo,Ag,In Ka 0.70000 Ang.

PLAT793_ALERT_4_G Model has Chirality at C11 (Centro SPGR) S Verify

PLAT860_ALERT_3_G Number of Least-Squares Restraints 132 Note

- 0 **ALERT level A** = Most likely a serious problem - resolve or explain
- 1 **ALERT level B** = A potentially serious problem, consider carefully
- 4 **ALERT level C** = Check. Ensure it is not caused by an omission or oversight
- 4 **ALERT level G** = General information/check it is not something unexpected
-
- 3 ALERT type 1 CIF construction/syntax error, inconsistent or missing data
- 1 ALERT type 2 Indicator that the structure model may be wrong or deficient
- 3 ALERT type 3 Indicator that the structure quality may be low
- 2 ALERT type 4 Improvement, methodology, query or suggestion
- 0 ALERT type 5 Informative message, check
-

It is advisable to attempt to resolve as many as possible of the alerts in all categories. Often the minor alerts point to easily fixed oversights, errors and omissions in your CIF or refinement strategy, so attention to these fine details can be worthwhile. In order to resolve some of the more serious problems it may be necessary to carry out additional measurements or structure refinements. However, the purpose of your study may justify the reported deviations and the more serious of these should normally be commented upon in the discussion or experimental section of a paper or in the "special_details" fields of the CIF. checkCIF was carefully designed to identify outliers and unusual parameters, but every test has its limitations and alerts that are not important in a particular case may appear. Conversely, the absence of alerts does not guarantee there are no aspects of the results needing attention. It is up to the individual to critically assess their own results and, if necessary, seek expert advice.

Publication of your CIF in IUCr journals

A basic structural check has been run on your CIF. These basic checks will be run on all CIFs submitted for publication in IUCr journals (*Acta Crystallographica*, *Journal of Applied Crystallography*, *Journal of Synchrotron Radiation*); however, if you intend to submit to *Acta Crystallographica Section C* or *E* or *IUCrData*, you should make sure that full publication checks are run on the final version of your CIF prior to submission.

Publication of your CIF in other journals

Please refer to the *Notes for Authors* of the relevant journal for any special instructions relating to CIF submission.

PLATON version of 18/02/2019; check.def file version of 18/02/2019

